MESO Mesoblast Limited

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced it will report financial results for the first quarter ended September 30, 2017 and provide a corporate update beginning at 4:30 pm ET on Tuesday, November 14, 2017 and 8:30 am AEDT on Wednesday, November 15, 2017.  

The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/59ff897e6afa4a0577a982bb

The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.

To access the call, dial 1 855 881 1339 (US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).

The conference identification code is: 303705.

The archived webcast will be available in the Events and Presentations section of the Investor page on the Company’s website – www.mesoblast.com

About MesoblastMesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.

For further information, please contact:

Julie Meldrum                                                               Corporate Communications                                         Mesoblast Limited                                                        T: +61 3 9639 6036                                                      E: julie.meldrum@mesoblast.com

Schond GreenwayInvestor RelationsMesoblast LimitedT: +1 212 880-2060E: Schond.Greenway@mesoblast.com